Immediately withhold ALECENSA treatment method in patients diagnosed with ILD/pneumonitis and completely discontinue ALECENSA if no other opportunity leads to of ILD/pneumonitis are already determined Individuals who had an incomplete antileukemic reaction acquired a second induction program by which mitoxantrone or daunorubicin was administered for two times and cytarabine for https://eldero529fko3.wikipublicity.com/user